JCP October Table of Contents E-Lert


The Journal of Clinical Psychiatry

Volume 74 • Number 10 • October 2013

Listen to an audio summary of this issue Publisher's Podcast: An Audio Summary of This Issue Subscribe to the Podcast
CME Commentary
See the complete CME Activity.
Preventing Domestic Violence in Families of Veterans
[Abstract] [Full Text] [CME Activity] [Audio Summary]
Clinical Points
  • Learn about resources for veterans and their families within your community.
  • Become familiar with military culture, especially the customs, habits, and norms that affect a veteran’s reaction to suggestions about mental health treatment.
  • Whenever possible, involve the significant other when treating someone for signs of deployment-related mental health stress.
Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies
Taishiro Kishimoto, Masahiro Nitta, Michael Borenstein, John M. Kane, and Christoph U. Correll
[Abstract] [Full Text] [Supplementary Material] [Audio Summary]
Clinical Points
  • Recent randomized controlled trials showed no benefit of long-acting injectables (LAIs) over oral antipsychotics in preventing relapse in schizophrenia.
  • The reported meta-analysis based on 25 mirror-image studies that compared periods of treatment with oral antipsychotics versus LAIs in the same patients, showed strong superiority of LAIs over oral antipsychotics in preventing hospitalization.
  • Mirror-image studies might better reflect the real-world impact of LAIs; however, one should consider the biases of different study designs when evaluating the comparative effectiveness of LAIs.
Original Research
Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial
Eric G. Smith, Kristina M. Deligiannidis, Christine M. Ulbricht, Chelsea S. Landolin, Jayendra K. Patel, and Anthony J. Rothschild
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • This placebo-controlled, double-blind randomized trial, although small, did not find efficacy for the oral N-Methyl-d-aspartate antagonist memantine as an augmentation treatment in major depressive disorder.
  • This study joins a placebo-controlled monotherapy trial and several other randomized controlled trials in suggesting a lack of efficacy for memantine against depression symptoms.


Treating Nicotine Dependence by Targeting Attention-Deficit/ Hyperactivity Disorder (ADHD) With OROS Methylphenidate: The Role of Baseline ADHD Severity and Treatment Response
Edward V. Nunes, Lirio S. Covey, Gregory Brigham, Mei-Chen Hu, Frances R. Levin, Eugene C. Somoza, and Theresa M. Winhusen
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • Attention-deficit/hyperactivity disorder (ADHD) is prevalent among individuals with nicotine dependence and reduces the likelihood of successfully quitting smoking.
  • Treatment of ADHD with stimulant medication may help nicotine-dependent patients quit smoking, particularly if the ADHD is more severe initially and if the ADHD symptoms are substantially improved by treatment.
  • Clinicians can help patients who are seeking to quit smoking by screening for and treating ADHD and optimizing ADHD treatment response (adjusting doses or changing medications if needed) before initiating a quit attempt with nicotine replacement.


Childhood Trauma Is Associated With Severe Clinical Characteristics of Bipolar Disorders
Bruno Etain, Monica Aas, Ole A. Andreassen, Steinar Lorentzen, Ingrid Dieset, Sebastien Gard, Jean-Pierre Kahn, Frank Bellivier, Marion Leboyer, Ingrid Melle, and Chantal Henry
[Abstract] [Full Text] [Supplementary Material] [Audio Summary]
Clinical Points
  • Childhood trauma, particularly emotional and sexual abuse, worsens the clinical expression of bipolar disorder.
  • Bipolar patients exposed to childhood trauma have an earlier age at illness onset, increased prevalence of suicide attempts and rapid cycling, and greater proneness toward depression.
  • Recognition of childhood trauma may help in the identification of patients with a more severe illness profile in order to personalize treatment strategies.
The Pervasive and Persistent Neurobiological and Clinical Aftermath of Child Abuse and Neglect
Charles B. Nemeroff and Fred Seligman
[Abstract] [Full Text]
Case Report
Lyme Neuroborreliosis Presenting With Alexithymia and Suicide Attempts
Rahul Banerjee, Jerome J. Liu, and Hassan M. Minhas
[Abstract] [Full Text]
Focus on Women’s Mental Health
Depression in Women: New Findings
Marlene P. Freeman
[Purchase] [Full Text]


A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body Mass Index and Metabolic Measures
Kristina M. Deligiannidis, Anthony J. Rothschild, Bruce A. Barton, Aimee R. Kroll-Desrosiers, Barnett S. Meyers, Alastair J. Flint, Ellen M. Whyte, and Benoit H. Mulsant, for the STOP-PD Study Group
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • One of the main novel findings of this gender analysis was that hallucinations and delusions with disorganization were more common among women with psychotic depression than men and that this finding was not associated with age.
  • Our analysis did not identify gender differences in treatment response in patients with psychotic depression, but it may have been limited by a small sample size.


Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder
Anita H. Clayton, Susan G. Kornstein, Boadie W. Dunlop, Kristen Focht, Jeff Musgnung, Tanya Ramey, Weihang Bao, and Philip T. Ninan
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • Depression in perimenopausal and postmenopausal women may be more common, and more difficult to treat, than depression in premenopausal women.
  • Desvenlafaxine, at the recommended dose of 50 mg/d, is an effective option for the treatment of depression in perimenopausal and postmenopausal women.
  • The safety and tolerability findings demonstrated with desvenlafaxine treatment in this study are similar to those observed in other desvenlafaxine clinical trials, supporting a favorable benefit/risk profile of desvenlafaxine in perimenopausal and postmenopausal women.


Female Reproductive Life Cycle and Hormones: Methodology to Improve Clinical Trials [Commentary]
Marlene P. Freeman, Rosemary Walker, Thomas P. Laughren, Karen K. Miller, and Maurizio Fava
[Abstract] [Full Text] [Audio Summary]

ASCP Corner
Decision Making and Antipsychotic Medication Treatment for Youth With Autism Spectrum Disorders: Applying Guidelines in the Real World
Stephanie H. Ameis, Patricia Corbett-Dick, Lynn Cole, and Christoph U. Correll
[Purchase] [Full Text]
Letters to the Editor
Phenoconversion of Cytochrome P450 2D6: The Need for Identifying the Intermediate Metabolizer Genotype
Elizabeth J. J. Berm, Arne J. Risselada, Hans Mulder, Eelko Hak, and Bob Wilffert
[Purchase] [Full Text]
• Reply by Sheldon H. Preskorn
[Purchase] [Full Text]


Borderline Personality Disorder Symptoms and Treatment Seeking Over the Past 12 Months: An Investigation Using the National Comorbidity Survey–Replication (NCS-R)
Edward A. Selby and R. Kathryn McHugh
[Purchase] [Full Text]

ONLINE Exclusives

Focus on Women’s Mental Health
Antecedent Trauma Exposure and Risk of Depression in the Perinatal Period
Emma Robertson-Blackmore, Frank W. Putnam, David R. Rubinow, Monica Matthieu, Julianne E. Hunn, Karen T. Putnam, Jan A. Moynihan, and Thomas G. O’Connor
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • Women with antecedent trauma history appear especially vulnerable to depressive episodes during pregnancy.
  • There was a clear dose-response effect of trauma on risk of antenatal depression, and trauma types conferred differential risk.
  • Routine screening for trauma exposure and depressive symptoms is warranted in pregnant women to aid in the early detection and treatment of depression.
Practical Psychopharmacology
Learning From History: How to Swallow a Pill
Chittaranjan Andrade
[Abstract] [Full Text] [Audio Summary]
Clinical Points
  • If pills are swallowed with little or no water, or if the patient lies down immediately after swallowing the pills, esophageal transit of the pills may be delayed; this can cause pill esophagitis, a preventable condition that is commoner in elderly subjects.
  • Pill esophagitis can also occur in conditions associated with narrowing of the esophageal lumen. Pill esophagitis is more likely with medications such as iron, alendronate, aspirin, anti-inflammatory drugs, antibiotics, and antimalarials.
  • The risk of pill esophagitis can be reduced by swallowing the pill with sufficient water, taking the pill before or during a meal, and staying upright for 15–30 minutes after pill ingestion. If these precautions are difficult to follow, administration of liquid formulations, orodispersible tablets, or crushed tablets can lower the risk.
Book Review
Management of Treatment-Resistant Major Psychiatric Disorders
Henry A. Nasrallah
[Purchase] [Full Text]
Free Online Activities
Mental Health Needs of Returning Veterans [CME]
Terence M. Keane, John P. Docherty, Robert L. Jesse, Jennifer Lee, Jessica McNurlen, and Eileen Zeller


Monitoring Treatment and Managing Adherence in Schizophrenia [CME]
Stephen R. Marder


You are receiving this update as a benefit of your membership

To ensure delivery of these messages add to your address book. If you would not like to receive further E-Lerts, go to and click the "Unsubscribe from E-Lerts " link. If you are having trouble unsubscribing, contact the web administrator for assistance

If you are having trouble with your membership, contact our circulation department. Direct any other questions or comments to the web administrator

Please do not reply directly to this e-mail

If you cannot read this go to

Physicians Postgraduate Press, Inc. | 850 Ridge Lake Boulevard, Suite 300 | Memphis, TN 38120

© Copyright 2013, Physicians Postgraduate Press, Inc. All rights reserved